PALM BEACH, Florida, January 9, 2018 /PRNewswire/ --
The growth in development for addressing healthcare, specifically unmet needs, as well as the ongoing and increasing need for developing the latest therapies and biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the healthcare industry over the long term. Technology has been developing at a fast pace and will be considered as a reliable tool for long-term health monitoring systems. The evolution of the internet of things (IOT) has a number of applications in healthcare, from distant monitoring to smart sensors and remedial device integration. Upbeat quarterly results, rise in demand for new product sales, successful innovation and product line expansion, strong clinical study results as well as a continued strong performance of legacy products propelled the healthcare sector to scale new highs in 2017. Moreover, these tailwinds are expected to drive the sector's growth in 2018. Active healthcare stocks in news today include: BioSig Technologies, Inc. (OTC: BSGM), OHR Pharmaceutical Inc. (NASDAQ: OHRP), Agenus Inc. (NASDAQ: AGEN), Galectin Therapeutics Inc. (NASDAQ: GALT), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR).
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has partnered with Mr. Charles (Chuck) Austin and JK Advisors in order to scale up operational activities ahead of the commercial launch of PURE EP(tm) System.
Mr. Austin brings to the Company over 25 years of experience in medical devices, pharmaceuticals and consumer products. Most recently, he served as Corporate Vice President, Global Supply Chain at Johnson & Johnson, and was a member of the J&J Management Committee. In this role, he was responsible for over 60,000 associates at 130 sites around the world while overseeing over 500 external manufacturers, over $22BB in direct spend, and supported in excess of $70BB in sales. His leadership positions within Johnson & Johnson included Company Group Chairman for Ethicon Surgical Care and Worldwide President for Ethicon Endo-Surgery. Read this and more news for BioSig Technologies at: http://www.marketnewsupdates.com/news/bsgm.html
The appointment of Mr. Austin comes at a crucial time for BioSig, as the Company executes its market entry in the U.S. in 2018. Mr. Austin currently serves on multiple boards in the medical and consumer spaces and is a Principal in JK Advisors, a San Diego based firm focused on the medical space.
"BioSig has impressed us with a strong value proposition and support of leading centers of excellence in the industry. I'm delighted to join the BioSig team at this important time and contribute my knowledge to take the Company to the next level," commented Mr. Austin.
"BioSig is excited to be working with an executive leader like Chuck. His 25 plus years of experience working for one of the world's leading healthcare organizations can significantly benefit our effort to launch and expand our business operations," stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc. "While we expect Chuck to make his initial impact on manufacturing, logistics, and operations, his experience in successfully deploying new commercial models and driving global growth in the medical device marketplace will create value for all our stakeholders. This is an excellent way to kick off our efforts in 2018, which promises to be a pivotal year for the Company."
In other healthcare industry news of note:
OHR Pharmaceutical Inc. (NASDAQ: OHRP) closed up 3.21% on Monday trading over 19.4 million shares market close and was also up slightly in afterhours trading. Last week, the company announced topline data from the MAKO study which did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration ("wet-AMD"). The primary efficacy endpoint was the mean visual acuity gain at nine months, using a mixed-effects model for repeated measures (MMRM) analysis. Subjects receiving squalamine combination therapy (n=119) achieved a mean gain of 8.33 letters from baseline versus 10.58 letters from baseline with Lucentis® monotherapy (n=118). There were no differences in the safety profile between the two treatment groups. "We are very disappointed with the outcome of the MAKO study," commented Dr. Jason Slakter, chief executive officer of Ohr. "We are grateful to the patients and physicians who participated in the clinical trial. Based on these results, we intend to evaluate strategic alternatives to maximize shareholder value."
Agenus Inc. (NASDAQ: AGEN) closed up over 11% on Monday at $3.91 trading over 5.8 million shares by the market close. The company also recently announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The transaction is comprised of $190 million of cash proceeds at closing plus up to $40 million in milestone payments. Agenus will use part of these proceeds to redeem its royalty bond from Oberland and the additional monies to advance its registrational studies with anti-CTLA-4 and anti-PD-1 for planned BLA filings in 2019 and 2020. At closing, HCR will receive the rights to royalties on sales of GlaxoSmithKline's QS-21 containing vaccines. Agenus retains all rights for the development of QS-21 with its entire portfolio of checkpoint antibodies, vaccines, and cellular therapies* with no third party obligation.
Galectin Therapeutics Inc. (NASDAQ: GALT) closed up Monday over 21% at $5.05 with over 1.8 million shares traded by the market close. Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis.
Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) closed up over 17% on Monday trading just over 6.9 million shares by the close. The company announced yesterday that it has entered into a European patent settlement and global license agreement with Teva Pharmaceuticals International GmbH (NYSE: TEVA). The agreement resolves Alder's appeal following opposition proceedings before the European Patent Office related to Teva's European Patent No. 1957106 B1, with respect to calcitonin gene-related peptide (CGRP) antagonist antibodies, and provides clarity regarding Alder's freedom to develop, manufacture and commercialize eptinezumab, its lead product candidate for migraine prevention targeting CGRP.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty-four hundred dollars for news coverage of the current press release issued by BioSig Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.